Business Context and Reporting Period
Company: Align Technology, Inc. (ALGN)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Align is a global medical device company primarily engaged in the design, manufacture, and marketing of Invisalign clear aligners, Vivera retainers, iTero intraoral scanners, and exocad CAD/CAM software. The company operates through two segments: Clear Aligner (approx. 80% of revenue) and Imaging Systems and CAD/CAM Services (approx. 20% of revenue). As of December 31, 2025, the company employed approximately 20,290 people globally.
Key Financial Metrics
| Metric | 2025 Value | 2024 Value |
|---|---|---|
| Total Net Revenues | $4,035.0 million | $3,999.0 million |
| Clear Aligner Revenues | $3,245.4 million | $3,230.1 million |
| Systems and Services Revenues | $789.6 million | $768.9 million |
| Gross Profit | $2,711.0 million | $2,799.2 million |
| Gross Margin | 67.2% | 70.0% |
| Income from Operations | $545.8 million | $607.6 million |
| Operating Margin | 13.5% | 15.2% |
| Net Income | $410.4 million | $421.4 million |
| Diluted EPS | $5.65 | $5.62 |
| Cash and Cash Equivalents | $1,094.9 million | $1,043.9 million |
| Operating Cash Flow | $593.2 million | $738.2 million |
| Capital Expenditures | $102.4 million | $115.6 million |
Material Changes vs. Prior Period
- Revenue Growth: Total net revenues increased 0.9% year-over-year. Clear Aligner revenue grew 0.5%, driven by a 4.7% increase in case volume, partially offset by a 3.9% decrease in revenue per case shipment due to product mix shifts and higher discounts. Systems and Services revenue grew 2.7%.
- Margin Compression: Gross margin decreased from 70.0% to 67.2%. This decline was primarily driven by restructuring charges, impairment losses on assets held for sale, accelerated depreciation on disposed assets ($76.9 million), and an inventory impairment loss ($15 million) in the Systems and Services segment.
- Operating Expenses: Selling, general, and administrative (SG&A) expenses decreased slightly ($7.4 million) due to lower employee and marketing costs. Research and development (R&D) expenses increased $5.7 million due to higher employee costs.
- Restructuring and Charges: The company incurred $41 million in restructuring expenses (primarily severance) and $23.1 million in impairment charges on assets held for sale (Juarez, Mexico facility) in 2025. Legal settlement losses decreased significantly to $4.2 million from $31.0 million in 2024.
- Case Volume: Total case volume increased 4.7% to 2.61 million. Teen and growing patient shipments increased 7.8% to 935.8 thousand.
Guidance, Outlook, and Risks
- Strategic Focus: Management continues to focus on international expansion, general practitioner (GP) adoption, patient demand generation, and orthodontic utilization. The company is investing in AI infrastructure and direct 3D printing capabilities (via the Cubicure acquisition) to enhance the Align Digital Platform.
- Macroeconomic Headwinds: Management cites global tariff volatility, inflation, higher interest rates, and geopolitical conflicts (Ukraine, Middle East) as factors impeding dental patient demand and discretionary spending. Orthodontic starts have been down for four consecutive years.
- Restructuring: The company initiated a restructuring plan in Q3 2025 to streamline operations and optimize its global manufacturing footprint. This includes the planned sale of the Juarez, Mexico facility and workforce reductions.
- Legal Proceedings: Significant ongoing litigation includes antitrust class actions (appeals pending), patent infringement suits against ClearCorrect/Straumann (trial set for June 2026), and multiple actions against Angelalign in the U.S., Europe, and China. A $31.75 million settlement was paid in 2025 regarding Section 1 antitrust claims.
- Tax Matters: A UK VAT dispute regarding clear aligners was settled in principle in 2024, with a refund of approximately $100 million received. However, HMRC has appealed a favorable Tax Tribunal ruling, with a hearing scheduled for May 2026.
Investor Verification Checklist
- Margin Sustainability: Verify the extent to which the 2.8% gross margin decline is due to one-time restructuring/impairment charges versus structural pricing pressure (ASP decline) and product mix shifts.
- Teen Market Growth: Confirm the sustainability of the 7.8% growth in teen case volume, as this demographic represents a key growth driver amidst broader market stagnation.
- Legal Exposure: Monitor the status of the antitrust appeals and the Straumann patent litigation, as adverse outcomes could result in significant financial penalties or operational restrictions.
- UK VAT Outcome: Track the May 2026 Upper Tribunal hearing regarding the UK VAT exemption for clear aligners, as an unfavorable ruling could impact future profitability in the region.
- Manufacturing Optimization: Assess the progress and cost savings associated with the restructuring of the manufacturing footprint, specifically the sale of the Juarez facility and the transition to direct 3D printing.